Biolinerx Ltd. · TASE:BLRX
Biolinerx — Investor Presentation (January 2017)
22 slides from Biolinerx's investor presentation, Jan 9, 2017
Slide 1: Corporate Presentation January 2017
Confidential property: Not to be used without written authorization from Health Science Communications. Corporate PresentationJanuary 2017
Slide 2: Forward-Looking Statements
* Forward-Looking Statements This presentation contains “forward-looking statements.”These statements include words like “may,” “expects,” “believes,” “plans,” “scheduled,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and
Slide 3: BioLineRx Snapshot
* Drug development company focused on oncology & immunology in three main areas:Immuno-oncology for multiple solid and liquid tumorsAcute myeloid leukemia (AML)Stem-cell mobilization for bone-marrow transplantationTransforming science into medicineWe leverage selected early-stage programs through ad
Slide 4: Main Pipeline Assets
* OTHER Main Pipeline Assets PROJECT INDICATION PARTNERS PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY APPROVAL CANCER IMMUNOLOGY Consolidation AML Maintenance AML Gastric cancer Non-small cell lung cancer Pancreatic cancer* Pancreatic cancer Stem-cell mobilization Celiac disease and gluten sensit
Slide 5: BL-8040 Best-in-class CXCR4 antagonist for multiple oncology indications
Confidential property: Not to be used without written authorization from Health Science Communications. BL-8040 Best-in-class CXCR4 antagonist for treatment of multiple oncology indications
Slide 6: BL-8040 Highlights
* BL-8040 Highlights Platform Molecule: Multiple cancer indicationsFocus on immunotherapy, AML and stem-cell mobilization (SCM)Received Orphan Designation from FDA for AML & SCMMode of Action: Inhibits CXCR4 (a cell surface protein)CXCR4 overexpressed in >70% of tumors; correlates with severity; wel
Slide 7: BL-8040 Clinical Development Program
* BL-8040 Clinical Development Program INDICATION PROTOCOL STEM CELL MOBILIZATION ONGOING PLANNED BL-8040.13 SCM (Autologous) Planned to initiate H2/2017
Slide 8: BL-8040 in Immuno-Oncology
Confidential property: Not to be used without written authorization from Health Science Communications. BL-8040 in Immuno-Oncology
Slide 9: BL-8040's MoA in Cancer Immunotherapy
* BL-8040’s MoA in Cancer Immunotherapy Immunostimulant - BL-8040 is a powerful mobilizer of immune cells from the bone marrow and lymph nodes (T-cells, B-cells, immature Dendritic-cells and NK-cells)Potentiator - BL-8040 increases infiltration of immune cells into tumors (exhibiting a synergistic e
Slide 10: Immunotherapy Collaboration with Genentech
* Immunotherapy Collaboration with Genentech Several phase 1b studies to investigate combination of BL-8040 with Genentech’s TecentriqTM, (anti-PDL1 immune checkpoint inhibitor) in multiple cancer indicationsGenentech to sponsor and conduct several phase 1b studies in multiple solid cancer indicatio
Slide 11: Immunotherapy Collaboration with Merck
* Immunotherapy Collaboration with Merck Phase 2a study to examine combination of BL-8040 with Merck’s Keytruda® (anti-PD1 immune checkpoint inhibitor) in pancreatic cancerUp to 30 patients with metastatic pancreatic adenocarcinomaOpen-label, multicenter, single-arm trialSites in the US, Israel and
Slide 12: BL-8040 in AML
Confidential property: Not to be used without written authorization from Health Science Communications. BL-8040 in AML
Slide 13: AML – Background and Direction
* AML – Background and Direction Company conducted successful proof-of-concept phase 2a study in relapsed/refractory AML38% composite remission rate versus 20% historical benchmarkShowed longer than expected durability of remissionsExcellent safety and tolerabilityShowed direct triple anti-leukemic
Slide 14: AML – Clinical Development Status
* AML – Clinical Development Status Consolidation AML phase 2b study ongoing194 patients, double-blind, placebo controlled at ~25 sites in GermanyEnrollment ongoingPotential interim results in 2018Maintenance AML phase 1b study (under Genentech collaboration) in late planning stagesCombination study
Slide 15: BL-8040 in SC Mobilization
Confidential property: Not to be used without written authorization from Health Science Communications. BL-8040 in SC Mobilization
Slide 16: Stem Cell Mobilization for Autologous Transplantation
* Stem Cell Mobilization for Autologous Transplantation G-CSF is current standard for autologous stem cell mobilization4-6 daily injections of G-CSF, plus 1-4 apheresis sessions required50-70% of patients are considered poor mobilizersFor poor mobilizers, 1-4 daily injections of Mozobil on top of G-
Slide 17: BL-8040 Summary
* BL-8040 Summary BL-8040 is a robust platform for multiple oncology indicationsImmunotherapyAMLStem-cell mobilization/transplantationBL-8040 has demonstrated robust efficacy in a number of clinical studiesCXCR4 is a validated targetBL-8040 has a clinically validated MoASignificant collaborations wi
Slide 18: Corporate Slides
Confidential property: Not to be used without written authorization from Health Science Communications. Corporate Slides
Slide 19: Strategic Collaboration with Novartis
* Strategic Collaboration with Novartis Novartis selected BioLineRx as its leading partner for identification and early development of Israeli-sourced drug candidatesExclusive first look at all Israeli-based projects scouted by BioLineRxCo-develop selected projects through clinical proof-of-concept
Slide 20: Well Funded
* Well Funded Cash position~$39 million as of September 30, 2016Funds operational capital through beginning of 2019Capital structureTraded on NASDAQ and TASE (Symbol: BLRX)56 million shares outstanding; 65 million fully dilutedUS shareholders represent ~70% of investor base, including key life-scien
Slide 21: Principal Expected Development Milestones in 2017/2018
* Principal Expected Development Milestones in 2017/2018 2018 2017 BL-8040 (Autologous SCM) phase 2/3 initiation BL-8040 (Pancreatic Cancer) phase 2 partial results BL-8040 (Allogeneic SCM) phase 2 partial results BL-8040 (Allogeneic SCM) phase 2 completion BL-8040 (AML Maintenance) phase 1b initiat
Slide 22: Thank You
* Philip SerlinChief Executive Officerwww.biolinerx.com +972-8-642-9100 Thank You